Wikipedia:WikiProject Chemicals/Chembox validation/VerifiedDataSandbox and A-423579: Difference between pages

| verifiedrevid = 477234900

| ImageFile = A-423,579.svg

| PIN = 4′-{3-[(3''R'')-3-(Dimethylamino)pyrrolidin-1-yl]propoxy}-3′,5′-difluoro[1,1′-biphenyl]-4-carbonitrile

| CASNo_Ref = {{cascite|changed|??}}

| CASNo = 461045-17-0

| UNII_Ref = {{fdacite|correct|FDA}}

| UNII = Q2CW3V5WGF

| PubChem1 = 22994515

| PubChem = 11349657

| PubChem_Comment = <small>(''R'')</small>

| ChemSpiderID1 = 13210784

| ChemSpiderID1_Ref = {{chemspidercite|correct|chemspider}}

| ChemSpiderID = 9524593

| ChemSpiderID_Ref = {{chemspidercite|correct|chemspider}}

| ChemSpiderID_Comment = <small>(''R'')</small>

| ChEMBL = 498228

| ChEMBL_Ref = {{ebicite|correct|EBI}}

| SMILES1 = CN(C)C1CCN(CCCOc2c(F)cc(cc2F):c2ccc(cc2)C#N)C1

| SMILES = CN(C)C1CCN(CCCOC2=C(F)C=C(C=C2F)C2=CC=C(C=C2)C#N)C1

| StdInChI = 1S/C22H25F2N3O/c1-26(2)19-8-10-27(15-19)9-3-11-28-22-20(23)12-18(13-21(22)24)17-6-4-16(14-25)5-7-17/h4-7,12-13,19H,3,8-11,15H2,1-2H3/t19-/m1/s1

| StdInChI_Ref = {{stdinchicite|correct|chemspider}}

| StdInChIKey = DJXFZKXYKKBTDR-LJQANCHMSA-N

| StdInChIKey_Ref = {{stdinchicite|correct|chemspider}}

| C=22 | N=3 | H=25 | O=1 | F=2

| MolarMass = 385.4502 g/mol

'''A-423,579''' is one of a range of [[histamine antagonist]]s developed by [[Abbott Laboratories]] which are selective for the [[Histamine H3 receptor|H₃]] subtype, and have [[stimulant]] and [[anorectic]] effects in animal studies making them potentially useful treatments for [[obesity]]. A-423,579 has improved characteristics over earlier drugs in the series with both high efficacy and low toxicity in studies on mice, and is currently in clinical development.<ref>{{cite journal |vauthors=Hancock AA, Diehl MS, Faghih R, Bush EN, Krueger KM, Krishna G, Miller TR, Wilcox DM, Nguyen P, Pratt JK, Cowart MD, Esbenshade TA, Jacobson PB |title=In vitro optimization of structure activity relationships of analogues of A-331440 combining radioligand receptor binding assays and micronucleus assays of potential antiobesity histamine H3 receptor antagonists |journal=Basic & Clinical Pharmacology & Toxicology |volume=95 |issue=3 |pages=144–52 |date=September 2004 |pmid=15447739 |doi=10.1111/j.1742-7843.2004.950307.x |doi-access=free }}</ref><ref>{{cite journal |vauthors =Hancock AA, Diehl MS, Fey TA, Bush EN, Faghih R, Miller TR, Krueger KM, Pratt JK, Cowart MD, Dickinson RW, Shapiro R, Knourek-Segel VE, Droz BA, McDowell CA, Krishna G, Brune ME, Esbenshade TA, Jacobson PB |title=Antiobesity evaluation of histamine H3 receptor (H3R) antagonist analogs of A-331440 with improved safety and efficacy |journal=Inflammation Research |volume=54 |issue= |pages=S27–9 |date=April 2005 |pmid=15928821 |doi=10.1007/s00011-004-0412-z |s2cid=22094031 }}</ref>

== References ==

{{Reflist}}

{{Histaminergics}}

[[Category:Fluoroarenes]]

[[Category:H3 receptor antagonists]]

[[Category:Benzonitriles]]

[[Category:4-Hydroxybiphenyl ethers]]

[[Category:Pyrrolidines]]

[[Category:Nitriles]]

{{Gastrointestinal-drug-stub}}